Drug prices One policy replaces legal shields for current rebates from drug manufacturers to pharmacy middlemen with protections for new, fixed arrangements that untie the payment amount from the price of the drug. (Photo: Shutterstock)

(Bloomberg) –The Trump administration Friday released two contentious drug policies, one that could cut profit margins for pharmaceutical companies and another that would allow them to make smaller payments to their partners.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.